SV2008002639A - Inhibidores macrociclicos del virus de hepatitis c ref. tip 101 slv - Google Patents
Inhibidores macrociclicos del virus de hepatitis c ref. tip 101 slvInfo
- Publication number
- SV2008002639A SV2008002639A SV2006002639A SV2006002639A SV2008002639A SV 2008002639 A SV2008002639 A SV 2008002639A SV 2006002639 A SV2006002639 A SV 2006002639A SV 2006002639 A SV2006002639 A SV 2006002639A SV 2008002639 A SV2008002639 A SV 2008002639A
- Authority
- SV
- El Salvador
- Prior art keywords
- optionally
- ring
- nitrogen
- formula
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 241000711549 Hepacivirus C Species 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 239000011593 sulfur Substances 0.000 abstract 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 230000001351 cycling effect Effects 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 abstract 1
- 229960000311 ritonavir Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
INHIBIDORES DE VHC DE FORMULA (I): (VER FORMULA); Y LOS N-ÓXIDOS, SALES Y FORMAS ESTEREOQUÍMICAMENTE ISOMÉRICAS DE ESTOS, EN LOS CUALES R1 ES ARILO O UN SISTEMA ANULAR SATURADO, PARCIALMENTE INSATURADO O COMPLETAMENTE INSATURADO DE 6 O 6 MIEMBROS, O UN SISTEMA ANULAR HETEROCICLICO BICICLO DE 8 A 12 MIEMBROS QUE CONTIENE UN NITRÓGENO, Y EN FORMA OPCIONAL UNO A TRES OXIGENO, AZUFRE O NITRÓGENO, DONDE DICHO SISTEMA ANULAR PUEDE ESTAR SUSTITUIDO EN FORMA OPCIONAL; L ES UN ENLACE DIRECTO, -O-, -O-ALCANDIILO C1-4-; -O-CO-, -O-C(=O)-NR5A- O -O-C(=O)-NR5A-ALCANDIILO-C1-4-; R2 ES HIDROGENO, -OR6, -C(=O)OR6, -C(=O)R7, -C(=O)NR5AR5B, -C(=O)NHR5C, -NR5AR5B, -NHR5C, -NHSOPNR5AR5B, -NR5ASOPR8, O -B(OR6)2; R3 Y R4 SON HIDROGENO O ALQUILO C1-6; O R3 Y R4 TOMADOS JUNTOS PUEDEN FORMAR UN ANILLO CICLOALQUILO C3-7; N ES 3, 4, 5 O 6; P ES 1 O 2; ARILO ES FENILO, NAFTILO, INDANILO, O 1, 2, 3, 4-TETRAHIDRONAFTILO, CADA UNO DE LOS CUALES PUEDE ESTAR SUSTITUIDO EN FORMA OPCIONAL HET ES UN ANILLO HETEROCICLO SATURADO, PARCIALMENTE INSATURADO O COMPLETAMENTE INSATURADO DE 5 O 6 MIEMBROS QUE CONTIENE 1 A 4 HETEROATOMOS SELECCIONADO CADA UNO EN FORMA INDEPENDIENTE DE NITRÓGENO, Y AZUFRE, QUE ESTA CONDENSADO EN FORMA OPCIONAL CON UN ANILLO BENCÉNICO, Y DONDE EL GRUPO HET COMO UN TODO PUEDE ESTAR SUSTITUIDO EN FORMA OPCIONAL; COMPOSICIONES FARMACEUTICAS QUE CONTIENEN COMPUESTOS (I) Y PROCESOS PARA PREPARAR LOS COMPUESTOS (I). TAMBIÉN SE PROPORCIONAN COMBINACIONES DISPONIBLES DE LOS INHIBIDORES DEL VHC DE FORMULA (I) CON RITONAVIR
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05107067 | 2005-07-29 | ||
| EP05107413 | 2005-08-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2008002639A true SV2008002639A (es) | 2008-07-23 |
Family
ID=37036843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2006002639A SV2008002639A (es) | 2005-07-29 | 2006-07-29 | Inhibidores macrociclicos del virus de hepatitis c ref. tip 101 slv |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7989471B2 (es) |
| EP (1) | EP1912995B1 (es) |
| JP (1) | JP5426163B2 (es) |
| KR (1) | KR101074673B1 (es) |
| CN (1) | CN101233137B (es) |
| AP (1) | AP2473A (es) |
| AR (1) | AR055104A1 (es) |
| AT (1) | ATE517902T1 (es) |
| AU (1) | AU2006274858B2 (es) |
| BR (1) | BRPI0614670A2 (es) |
| CA (1) | CA2617095C (es) |
| DK (1) | DK1912995T3 (es) |
| EA (1) | EA014646B1 (es) |
| GT (1) | GT200600341A (es) |
| IL (1) | IL188283A (es) |
| JO (1) | JO2768B1 (es) |
| MX (1) | MX2008001395A (es) |
| MY (1) | MY152153A (es) |
| NO (1) | NO20081071L (es) |
| NZ (1) | NZ564541A (es) |
| PE (1) | PE20070221A1 (es) |
| SG (1) | SG163613A1 (es) |
| SI (1) | SI1912995T1 (es) |
| SV (1) | SV2008002639A (es) |
| TW (1) | TWI412534B (es) |
| UY (1) | UY29705A1 (es) |
| WO (1) | WO2007014919A1 (es) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| DE602005017582D1 (en) | 2004-01-30 | 2009-12-24 | Medivir Ab | Hcv ns-3 serine protease inhibitoren |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| US7935670B2 (en) | 2006-07-11 | 2011-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008008502A1 (en) | 2006-07-13 | 2008-01-17 | Achillion Pharmaceuticals, Inc. | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008070358A2 (en) * | 2006-11-16 | 2008-06-12 | Phenomix Corporation | N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2008205116A1 (en) * | 2007-01-08 | 2008-07-17 | Phenomix Corporation | Macrocyclic hepatitis C protease inhibitors |
| US8937080B2 (en) | 2007-02-08 | 2015-01-20 | Medivir Ab | Pyrimidine substituted macrocyclic HCV inhibitors |
| WO2008096002A1 (en) * | 2007-02-08 | 2008-08-14 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting macrocyclic phosphonates and amidophosphates |
| US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| JP2011503201A (ja) | 2007-11-14 | 2011-01-27 | エナンタ ファーマシューティカルズ インコーポレイテッド | 大環状テトラゾリルｃ型肝炎セリンプロテアーゼ阻害剤 |
| US8273709B2 (en) | 2007-12-14 | 2012-09-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic HCV serine protease inhibitors |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| WO2009117594A1 (en) | 2008-03-20 | 2009-09-24 | Enanta Pharmaceuticals, Inc. | Fluorinated macrocyclic compounds as hepatitis c virus inhibitors |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2300491B1 (en) | 2008-05-29 | 2016-01-06 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX2011006244A (es) | 2008-12-10 | 2011-06-27 | Achillion Pharmaceuticals Inc | Nuevos peptidos de 4-amino-4-oxobutanoilo como inhibidores de replica viral. |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201040181A (en) * | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| CN101987825B (zh) * | 2009-07-31 | 2014-04-02 | 上海开拓者医药发展有限公司 | 一种2-氨基-3-甲基-4-甲氧基苯乙酮的制备方法 |
| CA2769652A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
| CA2822556A1 (en) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
| CN103380132B (zh) | 2010-12-30 | 2016-08-31 | 益安药业 | 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂 |
| TW201309690A (zh) | 2011-02-10 | 2013-03-01 | Idenix Pharmaceuticals Inc | 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途 |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX355102B (es) | 2012-01-11 | 2018-04-05 | Abbvie Ireland Unlimited Co | Procesos para hacer los inhibidores de la proteasa del hcv. |
| BR112015007887A2 (pt) | 2012-10-08 | 2017-07-04 | Abbvie Inc | compostos úteis para produzir inibidores hcv protease |
| SI2909205T1 (sl) | 2012-10-19 | 2017-02-28 | Bristol-Myers Squibb Company | 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij |
| EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| KR20160005334A (ko) | 2013-03-14 | 2016-01-14 | 아칠리온 파르마세우티칼스 인코포레이티드 | 소바프레비르 제조 방법 |
| WO2014145600A1 (en) | 2013-03-15 | 2014-09-18 | Achillion Pharmaceuticals, Inc. | Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof |
| US9006423B2 (en) | 2013-03-15 | 2015-04-14 | Achillion Pharmaceuticals Inc. | Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof |
| BR112015023351A2 (pt) | 2013-03-15 | 2017-07-18 | Achillion Pharmaceuticals Inc | forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| MA41812A (fr) * | 2015-03-27 | 2018-01-30 | Janssen Pharmaceuticals Inc | Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2189721T3 (es) | 1992-12-29 | 2003-07-16 | Abbott Lab | Inhibidores de proteasa retroviral. |
| IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
| US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| EP0902782A1 (en) | 1996-04-23 | 1999-03-24 | Vertex Pharmaceuticals Incorporated | Urea derivatives as inhibitors of impdh enzyme |
| DE69709671T2 (de) | 1996-10-18 | 2002-08-22 | Vertex Pharmaceuticals Inc., Cambridge | Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| ATE244717T1 (de) | 1997-03-14 | 2003-07-15 | Vertex Pharma | Inhibitoren des impdh-enzyms |
| JP4452401B2 (ja) | 1997-08-11 | 2010-04-21 | ベーリンガー インゲルハイム （カナダ） リミテッド | Ｃ型肝炎ウイルス阻害ペプチドアナログ |
| GB9818731D0 (en) * | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| EA004141B1 (ru) | 1999-03-19 | 2004-02-26 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы фермента impdh |
| UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| KR20040099425A (ko) * | 2002-04-11 | 2004-11-26 | 버텍스 파마슈티칼스 인코포레이티드 | 세린 프로테아제, 특히 ｃ형 간염 바이러스 ｎｓ3-ｎｓ4프로테아제의 억제제 |
| ATE422895T1 (de) * | 2003-04-16 | 2009-03-15 | Bristol Myers Squibb Co | Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus |
| US7125845B2 (en) * | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| DE602005017582D1 (en) | 2004-01-30 | 2009-12-24 | Medivir Ab | Hcv ns-3 serine protease inhibitoren |
| AU2006274861B2 (en) * | 2005-07-29 | 2012-11-08 | Medivir Ab | Macrocyclic inhibitors of hepatitis C virus |
| PE20070343A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
-
2006
- 2006-07-19 JO JO2006237A patent/JO2768B1/en active
- 2006-07-26 PE PE2006000917A patent/PE20070221A1/es not_active Application Discontinuation
- 2006-07-28 SG SG201005107-6A patent/SG163613A1/en unknown
- 2006-07-28 WO PCT/EP2006/064813 patent/WO2007014919A1/en not_active Ceased
- 2006-07-28 AU AU2006274858A patent/AU2006274858B2/en not_active Ceased
- 2006-07-28 NZ NZ564541A patent/NZ564541A/en not_active IP Right Cessation
- 2006-07-28 JP JP2008523375A patent/JP5426163B2/ja not_active Expired - Fee Related
- 2006-07-28 TW TW095127588A patent/TWI412534B/zh not_active IP Right Cessation
- 2006-07-28 DK DK06764264.5T patent/DK1912995T3/da active
- 2006-07-28 KR KR1020087003833A patent/KR101074673B1/ko not_active Expired - Fee Related
- 2006-07-28 EP EP06764264A patent/EP1912995B1/en active Active
- 2006-07-28 US US11/995,573 patent/US7989471B2/en not_active Expired - Fee Related
- 2006-07-28 AP AP2008004305A patent/AP2473A/xx active
- 2006-07-28 BR BRPI0614670-8A patent/BRPI0614670A2/pt not_active Application Discontinuation
- 2006-07-28 AT AT06764264T patent/ATE517902T1/de active
- 2006-07-28 MX MX2008001395A patent/MX2008001395A/es active IP Right Grant
- 2006-07-28 CN CN200680027654.7A patent/CN101233137B/zh not_active Expired - Fee Related
- 2006-07-28 SI SI200631129T patent/SI1912995T1/sl unknown
- 2006-07-28 GT GT200600341A patent/GT200600341A/es unknown
- 2006-07-28 UY UY29705A patent/UY29705A1/es unknown
- 2006-07-28 MY MYPI20063671 patent/MY152153A/en unknown
- 2006-07-28 AR ARP060103306A patent/AR055104A1/es unknown
- 2006-07-28 CA CA2617095A patent/CA2617095C/en not_active Expired - Fee Related
- 2006-07-28 EA EA200800484A patent/EA014646B1/ru not_active IP Right Cessation
- 2006-07-29 SV SV2006002639A patent/SV2008002639A/es unknown
-
2007
- 2007-12-20 IL IL188283A patent/IL188283A/en not_active IP Right Cessation
-
2008
- 2008-02-29 NO NO20081071A patent/NO20081071L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2008002639A (es) | Inhibidores macrociclicos del virus de hepatitis c ref. tip 101 slv | |
| SV2008002642A (es) | Inhibidores macrociclicos del virus de hepatitis c ref. pit 111 slv | |
| CL2011002377A1 (es) | Compuestos derivados de heterociclos triciclicos fusionados de anillo antraceno y bifenileno, inhibidores de proteína ns5a del virus de hepatitis c (vhc); composicion farmaceutica que los comprende; y uso del compuesto en la preparacion de un medicamento util en el tratamiento de hepatitis c. | |
| UY29016A1 (es) | Analogos de dipeptidos inhibidores de la hepatitis c | |
| CO6180506A2 (es) | Inhibidores de la proteasa ns3 del hcv | |
| AR061058A1 (es) | Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas | |
| PE20161573A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| AR064416A1 (es) | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. | |
| PE20060664A1 (es) | Amidas biciclicas como inhibidores de cinasa | |
| NI200700270A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| ES2422299T3 (es) | Indoles (4,5-dihidro) indoles tricíclicos | |
| PA8789901A1 (es) | Derivados de la 6-cicloamino-3-(piridazin-4-il)imidazol(1,2-b) priridazina, su preparación y su aplicación en terapéuta | |
| SV2009003258A (es) | Nuevos derivados aminopirimidina como inhibidores de plk1 | |
| ATE517897T1 (de) | Heterobicyclische inhibitoren von hvc | |
| PE20160751A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| PE20170249A1 (es) | Acidos carboxilicos heterociclicos como activadores de guanilato ciclasa soluble | |
| PE20121157A1 (es) | Compuestos heterociclicos como inhibidores de proteasas serinas | |
| PE20180478A1 (es) | Compuestos triciclicos y su uso como inhibidores de la fosfodiesterasa | |
| PE20091439A1 (es) | Compuestos triciclicos como antagonistas de crf | |
| PE20170295A1 (es) | Compuestos de imidazopiridazina | |
| PE20000011A1 (es) | Combinacion eficaz para el tratamiento de la impotencia | |
| CO6150181A2 (es) | Compuesto 6-(bencilo sustituido con heterociclo)-4-oxoquinolina y su uso como inhibidor de integrasa vih | |
| DE602005019241D1 (de) | Heterocyclische kondensierte verbindungen und ihre verwendung als antidiuretische mittel | |
| AR088982A1 (es) | Derivados de 2-yodo-imidazol | |
| CR11273A (es) | Derivados-2-ona disustituidos en 3, su preparacion y su aplicacion en terapeutica |